MPM Capital

General contacts
Investor type

PE / VC

Founded

1996

AUM

$3 000 M

Location

Boston, Massachusetts, United States

Investment Ticket

$10-50 m

Investment Stage

Series B Series A Seed Late Stage (Series C+)

Region of investment

North America Europe
Investor profile last updated: 16 August, 2026

Profile

MPM Capital is a venture capital firm focusing on healthcare and biotechnology, based in the United States. With over 30 years of experience, MPM Capital has played a pivotal role in the development of more than 60 FDA-approved drugs and facilitated over 120 M&A and IPO events. The firm is led by a team of seasoned professionals, including Ansbert Gadicke, M.D., Chairman, and Joseph Bolen, Ph.D., CEO. MPM Capital is distinguished by its commitment to transforming scientific breakthroughs into life-saving medicines.

The firm invests in private and public companies throughout the drug development process. MPM Capital's sector focus includes biotechnology, pharmaceuticals, MedTech, and life sciences. It supports series A through late-stage investments, primarily across North America. MPM Capital has accumulated substantial assets under management over its years of operation.

Notable portfolio companies of MPM Capital include Orna Therapeutics - circular RNA medicines, Aktis Oncology - radiopharmaceuticals for cancer treatment, Reunion - psychedelic-inspired pharmaceuticals for mental health, and argenx - immunology-focused biotech. Orna was notably acquired by Lilly for up to $2.4 billion.

Industry

Life Sciences Technology MedTech AI Software Pharmaceuticals Medical Devices Healthcare Services Biotechnology HealthTech Financial Services Fintech

MPM Capital Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region 		Size AUM Launch date
MPM Bio 2014 NVS Strategic Fund
Venture Capital (VC)
Biotechnology
Healthcare Services
Medical Devices
HealthTech
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$54 M
June 2014
MPM BioVentures 2014 LP
Venture Capital (VC)
Biotechnology
Financial Services
Fintech
Healthcare Services
Medical Devices
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$351 M
May 2015
MPM Oncology Impact Fund I
Venture Capital (VC)
Biotechnology
Financial Services
Fintech
Medical Devices
Pre-seed
Seed
Series A
North America
$5-10 m
$471 M
May 2016
MPM Oncology Innovations Fund
Venture Capital (VC)
Biotechnology
Financial Services
Fintech
Healthcare Services
Medical Devices
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$100 M
February 2019

Contacts

Name
Title
Email
Social Networks
avatar
Kristen Laguerre Managing Director, Chief Financial Officer and Chief Operating Officer
Managing Director, Chief Financial Officer and Chief Operating Officer
k•••@•••
LinkedIn
avatar
Frank Neumann, M.D., Ph.D. Entrepreneur Partner
Entrepreneur Partner
-
Upgrade to see contacts
avatar
PQCYb3EszlVGItHK PQCYb3EszlVGItHK
PQCYb3EszlVGItHK
[email protected]
linkedin twitter
avatar
PQCYb3EszlVGItHK PQCYb3EszlVGItHK
PQCYb3EszlVGItHK
[email protected]
linkedin twitter
avatar
PQCYb3EszlVGItHK PQCYb3EszlVGItHK
PQCYb3EszlVGItHK
[email protected]
linkedin twitter
Investment-team contacts for MPM Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about MPM Capital

MPM Capital is a venture capital and private equity firm. It backs companies at Series B, Series A, Seed and Late Stage (Series C+), writing tickets of $10-50 m.
MPM Capital is located in Boston, Massachusetts, United States.
MPM Capital was founded in 1996.
MPM Capital invests in companies and startups in Life Sciences, Technology, MedTech, AI, Software, Pharmaceuticals, Medical Devices, Healthcare Services, Biotechnology, HealthTech, Financial Services, Fintech.
MPM Capital invests in companies and startups in North America, Europe.
MPM Capital invests in companies and startups at Series B, Series A, Seed, Late Stage (Series C+).
MPM Capital usually invests $10-50 m on average.
MPM Capital has around $3 000m assets under management.
MPM Capital last fund was created/launched in 2019-02-27
MPM Capital can be reached through its website mpmbioimpact.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for MPM Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query MPM Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.